US Patent 11427567 Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
Patent 11427567 was granted and assigned to Incyte on August, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 15 May, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 8 May, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 12 Mar, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 12 Jan, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 27 Dec, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 16 Oct, 2023
Golden AI
Edits made to:
Infobox (+10 properties)
Infobox
Patent Inventor Names
Brandon Smith0
Jingwei Li0
Ken Mukai0
Liangxing Wu0
Margaret Favata0
Min Ye0
Qinda Ye0
Wenqing Yao0
Yingnan Chen0
Yvonne Lo0
Edits on 26 Apr, 2023
Golden AI
Infobox
Patent Citations
Edits on 21 Apr, 2023
Golden AI
Infobox
Edits on 23 Sep, 2022
Golden AI
Infobox
Edits on 31 Aug, 2022
Golden AI
Edits made to:
Infobox (+15 properties)
Article (+203 characters)
US Patent 11427567 Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
Article
The present application provides imidazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
11427567
Date of Patent
August 30, 2022
Patent Application Number
16992505
Date Filed
August 13, 2020
Patent Citations
Patent Primary Examiner
Find more entities like US Patent 11427567 Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
